NASDAQ: DAWNDay One Biopharmaceuticals Inc Stock
$7.19+0.19 (+2.71%)
Updated Jul 10, 2025
DAWN Price
$7.19
Fair Value Price
N/A
Market Cap
$728.80M
52 Week Low
$6.08
52 Week High
$16.76
P/E
-10.13x
P/B
1.52x
P/S
5.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$161.92M
Earnings
-$69.08M
Gross Margin
95%
Operating Margin
-38.25%
Profit Margin
-42.7%
Debt to Equity
0.11
Operating Cash Flow
-$87M
Beta
0.76
Next Earnings
Aug 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DAWN Overview
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with genetically defined cancers. Its lead product candidates are DAY101 and Pimasertib. Day One Biopharmaceuticals was incorporated in 2018 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DAWN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DAWN
Ranked#126 of 475
Ranked#126 of 475
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.52 | A | |
| $8.93 | A | |
| $45.17 | A |
Be the first to know about important DAWN news, forecast changes, insider trades & much more!
DAWN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DAWN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DAWN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DAWN is good value based on its book value relative to its share price (1.52x), compared to the US Biotechnology industry average (4.7x)
P/B vs Industry Valuation
DAWN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DAWN due diligence checks available for Premium users.
Valuation
DAWN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.13x
Industry
-162x
Market
30.8x
DAWN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.52x
Industry
4.7x
DAWN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DAWN's financial health
Profit margin
Revenue
$30.8M
Net Income
-$36.0M
Profit Margin
-117%
DAWN's Earnings (EBIT) of -$61.94M... subscribe to Premium to read more.
Interest Coverage Financials
DAWN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$534.4M
Liabilities
$54.8M
Debt to equity
0.11
DAWN's short-term assets ($508.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DAWN's short-term assets ($508.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DAWN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$59.0M
Investing
-$32.6M
Financing
$0.0
DAWN's operating cash flow (-$87.38M)... subscribe to Premium to read more.
Debt Coverage Financials
DAWN vs Biotech Stocks
Day One Biopharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.